Researchers Submit Patent Application, "Driving Axon Regeneration By Nrf2 Overexpression And Edaravone Application", for Approval (USPTO 20240374570).

Researchers have submitted a patent application for a method to promote axon regeneration in individuals with central nervous system (CNS) injuries by activating nuclear factor erythroid 2-related factor 2 (Nrf2) using edaravone. The application aims to address the challenges of axon regeneration after CNS injuries by targeting intrinsic factors. The method involves administering edaravone to induce Nrf2 activation, which has shown promising results in promoting axon growth and enhancing neuron survival in subjects with CNS injuries. [Extracted from the article]